All In Biotech

Drug Trial Radar · NCT06920004

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Aug 22, 2025

Primary completion

Sep 2027

Study completion Sep 2030

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Apr 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • CIDP
  • CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

  • empasiprubartBiological

    Intravenous infusion of empasiprubart

  • IVIgBiological

    Intravenous infusion of IVIg

  • empasiprubart-placeboOther

    A placebo resembling the empasiprubart treatment

  • IVIg-placeboOther

    A placebo resembling the IVIg treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of ≥1 point compared with baseline in aINCAT score at week 24Time frame: up to 24 weeks

Locations

109 sites in 31 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama · Recruiting

  • Banner University of Arizona Medical Center

    Tucson, Arizona · Recruiting

  • Samir Macwan, M.D., Inc.

    Rancho Mirage, California · Recruiting

  • Colorado Springs Neurological Associates

    Colorado Springs, Colorado · Recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Homestead Associates in Research Inc

    Homestead, Florida · Recruiting

  • Visionary Investigators Network

    Miami, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Baptist Health Medical Group Neurology

    Nicholasville, Kentucky · Recruiting

  • Paradigm Health System

    Slidell, Louisiana · Recruiting

  • Erlanger Health System

    Columbia, Maryland · Recruiting

  • University of Michigan Hospital

    Ann Arbor, Michigan · Recruiting

  • University of North Carolina Hospital

    Chapel Hill, North Carolina · Recruiting

  • University of Cincinnati Health

    Cincinnati, Ohio · Recruiting

  • Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania · Recruiting

  • Jefferson Health Honickman Center

    Philadelphia, Pennsylvania · Recruiting

  • University Neurology

    Knoxville, Tennessee · Recruiting

  • NeuroCarePlus

    Houston, Texas · Recruiting

  • National Neuromuscular Research Institute

    Irving, Texas · Recruiting

  • Instituto Privado Kremer

    Córdoba, Argentina · Recruiting

  • INECO Neurociencias Oroño

    Rosario, Argentina · Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

  • Kepler Universitätsklinikum Linz - Med Campus III

    Linz, Austria · Recruiting

  • Universitätsklinikum AKH Wien

    Vienna, Austria · Recruiting

  • Hospital Moinhos de Vento

    Porto Alegre, Brazil · Recruiting

  • Escola Bahiana de Medicina e Saude Publica

    Salvador, Brazil · Recruiting

  • PSEG Centro de Pesquisa Clinica

    São Paulo, Brazil · Recruiting

  • PSEG Centro de Pesquisa Clinica - Rua Borges Lagoa 1060

    São Paulo, São Paulo, Brazil · Recruiting

  • University of Alberta

    Edmonton, Canada · Recruiting

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • Black Tusk Research Group

    Vancouver, British Columbia, Canada · Recruiting

  • Hospital Universitario San Ignacio

    Bogotá, Colombia · Recruiting

  • Hospital Alma Máter de Antioquia

    Medellín, Colombia · Recruiting

  • Hospital Neurologico de Colombia Fundacion Ivan Jimenez - El Neurologico

    Medellín, Colombia · Recruiting

  • Fakultni nemocnice Brno

    Brno, Czechia · Recruiting

  • Astra Kliinik

    Tallinn, Estonia · Recruiting

  • Tartu University Hospital

    Tartu, Estonia · Recruiting

  • CHU de Bordeaux - Hôpital Pellegrin

    Bordeaux, France · Recruiting

  • AP-HP - Hôpital Bicêtre

    Le Kremlin-Bicêtre, France · Recruiting

  • CHU de Nice-Hôpital Pasteur

    Nice, France · Recruiting

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.